in ,

Pediatric Nephrologists Awarded $3M NIH Grant for APOL1 and HIV Synergy Research

Scanning electron micrograph of HIV particles infecting a human H9 T cell, colorized in blue, turqoise, and yellow. Credit: NIAID

For more than 25 years, Children’s National pediatric nephrology program has studied the relationship between HIV and renal diseases in children.

The team recently developed Drosophila APOL1-G0 and G1 transgenic lines, pioneering research which suggests that HIV-1 acts as a “second hit,” precipitating HIV-renal disease in children by infecting podocytes through a mechanism that increases expression of the APOL1-RA beyond toxic thresholds.

With a new infusion of funding from the National Institutes of Health (NIH), labs led by Zhe Han, Ph.D., and Patricio E. Ray, M.D., will determine the phenotype of Drosophila Tg lines that express APOL1-G0/G1/G2 and four HIV genes in nephrocytes to assess how they affect structure and function. The teams also will determine whether APOL1-RA precipitates the death of nephrocytes expressing HIV genes by affecting autophagic flux.

“Our work will close a critical gap in understanding about how HIV-1 interacts with the APOL1 risk variants in renal cells to trigger chronic kidney disease, and we will develop the first APOL1/HIV transgenic fly model to explore these genetic interactions in order to screen new drugs to treat these renal diseases,” says Dr. Ray, a Children’s nephrologist.

The APOL1 genetic variants G1 and G2, found almost exclusively in people of African ancestry, lead to a four-fold higher risk of end-stage kidney disease. HIV infection alone also increases the risk of kidney disease but not significantly. However, HIV-positive people who also carry the APOL1 risk alleles G1 or G2 are about 30 times more likely to develop HIV-nephropathy (HIVAN) and chronic kidney disease.

While a large number of people from Africa have two copies of APOL1 risk alleles, they do not necessarily develop kidney disease. However, if a patient has two copies of APOL1 risk alleles and is HIV-positive, they almost certainly will develop kidney disease.

“Many teams want to solve the puzzle of how APOL1 and HIV synergize to cause kidney failure,” says Han, associate professor in Children’s Center for Genetic Medicine Research. “We are in the unique position of combining a powerful new kidney disease model system, Drosophila, with long-standing human podocyte and HIVAN studies.”

The team hypothesizes that even as an active HIV infection is held in check by powerful new medicines, preventing the virus from proliferating or infecting new cells, HIV can act as a Trojan horse by making the human cells it infects express HIV protein.

To investigate this hypothesis, the team will create a series of fly models, each expressing a major HIV protein, and will test the genetic interaction between these HIV genes with APOL1. Similar studies also will be performed using cultured human podocytes. Identified synergy will be studied further using biochemical and transcription profile analyses.

“Drosophila is a basic model system, but it has been used to make fundamental discoveries, including genetic control of how the body axes is determined and how the biological clock works – two studies that led to Nobel prizes,” Han adds. “I want to use the fly model to do something close to human disease. That is where my research passion lies.”

The research investment from the NIH is valued at $3 million over five years.

Pediatric Nephrologist Patricio Ray Researching HIV Role in Kidney Disease
Pediatric Nephrologist Patricio Ray, M.D., leader of one of the labs spearheading the APOL1 HIV research under the NIH funding grant. Credit: Children’s National

Disease Detectives Investigate Plague Outbreak

Attack on Ebola Treatment Center, Marburg Virus Vaccine Funding, Mumps Outbreak

Nanoscale CBRN Defense

CRADA Opportunity: Developing Protein Nanoparticles for the Display of Viral Epitopes